Document is current
Any future updates will be listed below
-
Authors
Gurule, Natalia J.
Malcolm, Kenneth C.
Harris, Chelsea https://orcid.org/0000-0002-1471-8764
Knapp, Jennifer R. https://orcid.org/0000-0003-4342-5378
O’Connor, Brian P.
McClendon, Jazalle
Janssen, William J.
Lee, Frank Fang Yao https://orcid.org/0000-0001-8458-3116
Price, Caitlin
Osaghae-Nosa, Jackson
Wheeler, Emily A.
McMahon, Christine M. https://orcid.org/0000-0001-9745-9595
Pietras, Eric M.
Pollyea, Daniel A.
Alper, Scott https://orcid.org/0000-0002-2411-2037
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (R01AI155749)
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (R01AI155749, R01HL148335)
Wendy Siegel Fund for Leukemia and Cancer Research Viola Vestal Coulter Foundation
- License Information
-
More Information
Article History
Received: 28 May 2023
Revised: 24 July 2023
Accepted: 8 August 2023
First Online: 17 August 2023
Competing interests
: The authors have declared that no conflict of interest exists with regard to this work. DAP receives research funding from Abbvie, Karyopharm, Bristol Myers Squibb and Teva, and served as a consultant or advisory board member for Novartis, Abbvie, BeiGene, Bergen Bio, Arcellx, Jazz, Genentech, Syros, Bristol Myers Squibb, Immunogen, Astra Zeneca, Kura, Ryvu, Magenta, Qihan, Zentalis, Medivir, Hibercell, LINK, Daiichi Sankyo, Sumitomo, Adicet, Seres, Gilead, OncoVerity, Boehringer Ingelheim, and Sanofi.
